Enanta Pharmaceuticals (NASDAQ: ENTA) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drugs for viral infections and other diseases. The company does not generate product revenue from commercial sales; instead, it has funded operations through a royalty sale agreement with OCM Life Sciences Portfolio LP (an affiliate of OMERS), executed April 25, 2023, under which it received proceeds in exchange for future royalty streams. Enanta carries a liability on its balance sheet related to this royalty sale, and its cash position is supported by marketable securities holdings. The company qualifies as a smaller reporting company as of March 31, 2024, with annual revenues below $100 million. Operating expenses are concentrated in research and development and general and administrative costs, with R&D accruals representing a critical audit matter given the judgment required to estimate progress on drug development programs and pharmaceutical manufacturing activities.

Revenue model

Enanta does not generate commercial product revenue. It has monetized future royalty streams through a royalty sale agreement with OCM Life Sciences Portfolio LP dated April 25, 2023, receiving upfront proceeds recorded as a financing liability. Interest expense and non-cash royalty revenue are recognized as the royalty liability is repaid over time.

Products and services

Small molecule drug candidates targeting viral infections and other diseases, at clinical-stage development. No commercially approved products are identified in the filing excerpts.

Customers and end markets

No commercial customers or end-market revenue concentration data are disclosed in the filing excerpts. The company's pipeline targets viral infection indications subject to Medicare and Medicaid reimbursement frameworks, including IRA-related Part D redesign provisions effective in calendar year 2025.

Value-chain role

Drug discovery and clinical development organization. Enanta functions as a research and development stage company without commercial manufacturing or direct sales operations.

Geographic exposure

No geographic revenue breakdown is disclosed in the filing excerpts. The company is incorporated in the United States and files with the SEC under Commission File Number 001-35839.

Source: SEC 10-K, filed 2025-11-19

Industry: Pharmaceutical Preparations Peers: Vericel Corp Arcutis Biotherapeutics Inc Avid Bioservices, Inc. Avidity Biosciences, Inc. Crinetics Pharmaceuticals Inc Emergent BioSolutions Inc ImmunoGen, Inc. Madrigal Pharmaceuticals Inc Sana Biotechnology Inc